LONDON–( SERVICE CORD)– Closed Loophole Medication Ltd., a leader in AI-enabled accuracy medications, today introduced the growth of its United States license profile. Enhancing its cardiometabolic therapy profile, the Firm currently has licenses covering developments in GLP-1 treatments for weight problems and diabetes mellitus, and straight dental anticoagulants (DOACs) for cardio health and wellness. Closed Loophole Medication holds over 65 filings throughout 16 license households, noting a considerable landmark in its objective to provide p.
发布者：Dr.Durant，转转请注明出处：https://robotalks.cn/us-patent-office-grants-closed-loop-medicine-key-patents-for-cardiometabolic-capabilities-in-glp-1-and-direct-oral-anti-coagulants-doac-therapies/
